Myocardial fatty acid metabolism is the process by which free fatty acids entering cardiac cells undergo beta-oxidation in the mitochondria of cardiac cells to provide energy for the mechanical activities of the heart.
The beta-oxidation of long-chain fatty acids in cardiomyocyte provides the bulk of energy to sustain the continuous contractile activity of the heart and the ion concentration gradient in and out of cardiomyocytes.
Free fatty acids (FFAs) enter the cardiomyocytes by passive diffusion or by protein-mediated sarcolemmal transport that includes a fatty acid translocase or plasma membrane fatty acid-binding protein. The bulk of fatty acids entering the cell are quickly oxidized in mitochondria, while a small portion is converted to structural lipids or stored as intracardiac triglycerides.
First, fatty acyl CoA synthase catalyzes fatty acids into fatty acyl CoA. Carnitine palmitoyltransferase 1 (CPT-1) stimulates the catalysis of fatty acyl CoA and carnitine into acylcarnitine. Acylcarnitine subsequently enters into the mitochondrial matrix through the mitochondrial membrane via carnitine acyltranslocase. Under the action of CPT-2 on the inner side of the mitochondrial membrane, the lipid acylcarnitine releases carnitine and fatty acyl CoA. The released fatty acyl CoA undergoes beta-oxidation and generates NADH flavin adenine dinucleotide (FADH2).
With an in-depth study of myocardial fatty acid metabolism, scientists have found that many diseases are accompanied by changes in myocardial fatty acid metabolism. Regulating the metabolism of cardiac fatty acids is beneficial to the treatment of cardiovascular diseases. Studies have shown that the occurrence of diabetic cardiomyopathy is closely related to abnormal fatty acid metabolism of the heart. Its main manifestation is that the diabetic heart significantly increases the uptake ＆ oxidation of fatty acids in cardiomyocytes and the accumulation of TAG in cardiomyocytes. Both the two conditions can lead to cardiomyopathy and impair heart function. Therefore, measures that regulate the metabolism of fatty acids in myocardium should be helpful in the prevention and treatment of diabetic cardiomyopathy.
In addition, some other diseases such as ischemic heart disease, cardiomyopathy, and heart failure, are closely associated with cardiac fatty acid metabolism. These findings suggest that the regulation of myocardial metabolism of fatty acids should be considered in the selection of prevention and treatment.
|ACAA1||ACAA1 Antibody||ACAA1 Protein||ACAA1 cDNA||ACAA1 ELISA Kit|
|ACACA||ACACA Antibody||ACACA Protein||ACACA cDNA||ACACA ELISA Kit|
|ACOT2||ACOT2 Antibody||ACOT2 Protein||ACOT2 cDNA||ACOT2 ELISA Kit|
|ANGPTL4||ANGPTL4 Antibody||ANGPTL4 Protein||ANGPTL4 cDNA||ANGPTL4 ELISA Kit|
|ATP5A1||ATP5A1 Antibody||ATP5A1 Protein||ATP5A1 cDNA||ATP5A1 ELISA Kit|
|ATP5J2||ATP5J2 Antibody||ATP5J2 Protein||ATP5J2 cDNA||ATP5J2 ELISA Kit|
|CPT1A||CPT1A Antibody||CPT1A Protein||CPT1A cDNA||CPT1A ELISA Kit|
|CPT2||CPT2 Antibody||CPT2 Protein||CPT2 cDNA||CPT2 ELISA Kit|
|DPP4||DPP4 Antibody||DPP4 Protein||DPP4 cDNA||DPP4 ELISA Kit|
|MLYCD||MLYCD Antibody||MLYCD Protein||MLYCD cDNA||MLYCD ELISA Kit|
|PPA1||PPA1 Antibody||PPA1 Protein||PPA1 cDNA||PPA1 ELISA Kit|
|PPARA||PPARA Antibody||PPARA Protein||PPARA cDNA||PPARA ELISA Kit|
|PPARGC1A||PPARGC1A Antibody||PPARGC1A Protein||PPARGC1A cDNA||PPARGC1A ELISA Kit|
|PRKAA2||PRKAA2 Antibody||PRKAA2 Protein||PRKAA2 cDNA||PRKAA2 ELISA Kit|
|RXRA||RXRA Antibody||RXRA Protein||RXRA cDNA||RXRA ELISA Kit|
|RXRB||RXRB Antibody||RXRB Protein||RXRB cDNA||RXRB ELISA Kit|
|RXRG||RXRG Antibody||RXRG Protein||RXRG cDNA||RXRG ELISA Kit|
|SLC27A1||SLC27A1 Antibody||SLC27A1 Protein||SLC27A1 cDNA||SLC27A1 ELISA Kit|
|UCP1||UCP1 Antibody||UCP1 Protein||UCP1 cDNA||UCP1 ELISA Kit|